Please login to the form below

Not currently logged in
Email:
Password:

GLP-1

This page shows the latest GLP-1 news and features for those working in and with pharma, biotech and healthcare.

News: Charity criticises NHS England and Vertex over Orkambi access, Sema scores again, NodThera launched

News: Charity criticises NHS England and Vertex over Orkambi access, Sema scores again, NodThera launched

One key battleground in the sector is between GLP-1 drugs, with Lilly’s Trulicity looking to challenge Novo Nordisk’s market leader Victoza – but Novo is sweeping all before it

Latest news

  • Novo’s diabetes pill defeats Merck’s Januvia in trial Novo’s diabetes pill defeats Merck’s Januvia in trial

    Comparing oral semaglutide to Merck &Co’s DPP-4 inhibitor Januvia (sitagliptin), PIONEER 7 investigated the efficacy and safety of the GLP-1 inhibitor in people with type 2 diabetes. ... Novo is already a big player in the diabetes setting, with

  • FDA starts review of Sanofi’s oral type 1 diabetes drug FDA starts review of Sanofi’s oral type 1 diabetes drug

    as stimulating the release of GLP-1. ... Lexicon exercised an option to co-promote the drug in the US  for the treatment of type 1 diabetes last year.

  • Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1 Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

    Novo Nordisk fends off Lilly’ s GLP-1 challenge in Q1. Insulin specialist bounces back with encouraging signs from Ozempic launch. ... After correcting for currency exchange factors, once-daily injectable GLP-1 agonist Victoza (liraglutide) grew 18% to

  • Novo Nordisk’s semaglutide obesity trial hits the mark Novo Nordisk’s semaglutide obesity trial hits the mark

    Novo Nordisk’s run of good news with GLP-1 agonist semaglutide has continued with a mid-stage trial showing it can achieve significant weight loss in adults with obesity. ... Overall, 83% of patients treated with the drug lost 5% or more of their body

  • Novo's oral semaglutide ‘safe and well-tolerated’ Novo's oral semaglutide ‘safe and well-tolerated’

    PIONEER 1, oral semaglutide’s first phase III study, investigated its safety and efficacy in in adults with type 2 diabetes who took 3, 7 and 14mg doses of the drug ... Ozempic. That particular trial, SUSTAIN 7, saw Lilly’s blockbuster beaten by

More from news
Approximately 12 fully matching, plus 140 partially matching documents found.

Latest Intelligence

  • Harnessing commercial innovation Harnessing commercial innovation

    These efforts moved up a gear last year when Novo decided to enter into phase III trials with an oral GLP-1.

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    like peptide-1 (GLP-1), a hormone that works independently of insulin to stimulate glucose release. ... Oramed - whose technology relies on encapsulating the peptide or protein and delivering it alongside enzyme inhibitors and permeation enhancers - has

  • Deal Watch November 2015 Deal Watch November 2015

    Included in the package are three products: a weekly insulin, a fixed weekly dose combination of GLP-1-RA/insulin and efpeglenatide, a long acting glucagon like peptide-1 receptor agonist. ... 6, 546. Hanmi Pharmaceutical. Sanofi. Licence. Three diabetes

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    400. Inarcia therapeutics / Investors. Synthetic royalty rights. ICTA650 extended sub-cutaneous delivery of GLP-1 for T2DM.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Licence collaboration agreement. 1, 110. Janssen/ Depomed. Nucynta [tapentadol] franchise including extended release tablets and oral solutions. ... Asset acquisition. 142. Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in T2

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics